Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
ADMA Biologics, Inc.'s quarterly P/E stands at 24.4x, down 26.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 42.5% YoY to 17.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 19.22 | 24.43 | 32.52 | 45.09 | 9.32 | 33.32 | 21.50 | 21.91 | — | 81.36 | — | — | — |
| — | -26.7% | +51.2% | +105.8% | — | -59.1% | — | — | — | — | — | — | — | |
| P/S Ratio | 8.70 | 6.68 | 9.28 | 10.57 | 8.97 | 10.21 | 6.31 | 4.76 | 3.46 | 3.11 | 3.42 | 3.23 | 3.94 |
| — | -34.6% | +46.9% | +121.9% | +159.6% | +228.3% | +84.8% | +47.7% | -12.2% | +7.1% | +19.2% | +4.8% | +62.9% | |
| P/B Ratio | 10.86 | 8.32 | 11.37 | 13.00 | 12.08 | 21.10 | 14.38 | 10.15 | 7.55 | 5.53 | 5.60 | 5.04 | 5.18 |
| — | -60.6% | -21.0% | +28.1% | +60.0% | +281.9% | +156.8% | +101.3% | +45.9% | +16.2% | +64.7% | +78.6% | +186.7% | |
| P/FCF | 33.71 | — | 60.47 | — | 22.21 | 51.03 | 15.53 | — | 15.57 | 18.63 | — | — | — |
| — | — | +289.3% | — | +42.7% | +173.9% | — | — | — | — | — | — | — | |
| EV / EBITDA | 25.10 | 17.01 | 25.20 | 33.00 | 26.05 | 29.57 | 16.73 | 17.30 | 17.00 | 21.24 | 140.11 | 168.25 | — |
| — | -42.5% | +50.6% | +90.8% | +53.2% | +39.2% | -88.1% | -89.7% | — | — | — | — | — | |
| EV / EBIT | 26.55 | 18.34 | 26.95 | 34.33 | 27.91 | 30.55 | 17.41 | 18.68 | — | 25.54 | — | — | — |
| — | -40.0% | +54.8% | +83.8% | — | +19.6% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
ADMA Biologics, Inc.'s operating margin was 38.0% in Q3 2025, up 2.9 pp QoQ and up 4.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 34.0% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 13.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.5% | 56.3% | 55.1% | 53.2% | 53.9% | 49.8% | 53.6% | 47.8% | 42.1% | 36.6% | 27.8% | 29.0% | 28.4% |
| — | +13.2% | +2.8% | +11.4% | +28.1% | +35.9% | +93.1% | +64.6% | +48.3% | +55.9% | +21.1% | +130.6% | +113.1% | |
| Operating Margin | 32.6% | 38.0% | 35.1% | 30.4% | 32.6% | 33.1% | 36.6% | 26.7% | 19.3% | 12.9% | -0.8% | -1.4% | -12.1% |
| — | +14.9% | -4.1% | +14.0% | +69.3% | +156.2% | +4748.7% | +1965.7% | +258.9% | +156.9% | +97.1% | +97.2% | +75.8% | |
| Net Margin | 46.4% | 27.1% | 28.1% | 23.4% | 95.2% | 30.0% | 29.9% | 21.7% | -23.9% | 3.8% | -10.6% | -11.9% | -24.5% |
| — | -9.4% | -6.2% | +7.8% | +498.7% | +685.9% | +382.3% | +282.3% | +2.4% | +110.5% | +73.9% | +86.1% | +61.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 81.6% | 8.8% | 8.9% | 7.4% | 38.5% | 17.1% | 18.8% | 12.3% | -12.3% | 1.7% | -4.4% | -4.6% | -9.7% |
| — | -48.6% | -52.7% | -39.6% | +412.9% | +893.6% | +530.3% | +370.2% | -27.0% | +112.4% | +61.8% | +75.5% | +29.0% | |
| ROA | 48.3% | 6.5% | 6.4% | 5.4% | 25.5% | 9.4% | 8.8% | 5.2% | -5.2% | 0.7% | -1.9% | -2.0% | -3.8% |
| — | -31.0% | -27.4% | +2.8% | +589.1% | +1163.1% | +573.2% | +365.8% | -38.0% | +114.9% | +59.1% | +77.0% | +41.7% | |
| ROIC | 37.7% | 9.1% | 8.3% | 7.4% | 9.8% | 11.9% | 12.0% | 6.9% | 4.7% | 2.8% | -0.2% | -0.3% | -2.1% |
| — | -24.1% | -30.9% | +6.7% | +109.8% | +327.1% | +7995.9% | +2653.6% | +325.9% | +186.3% | +95.4% | +95.2% | +61.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
ADMA Biologics, Inc.'s Debt/EBITDA ratio is 1.6x, down from 1.9x last quarter — comfortably within a safe range. Debt/Equity has declined for 8 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.19 | 0.21 | 0.22 | 0.24 | 0.48 | 0.75 | 0.92 | 1.05 | 1.01 | 1.03 | 1.07 | 1.02 |
| — | -59.9% | -72.0% | -76.1% | -77.5% | -52.4% | -27.3% | -13.9% | +2.9% | -33.6% | -21.9% | -7.3% | +39.4% | |
| Debt / EBITDA | 0.56 | 1.57 | 1.87 | 2.23 | 2.04 | 2.68 | 3.43 | 5.91 | 8.65 | 14.19 | 93.24 | 127.64 | — |
| — | -41.5% | -45.5% | -62.3% | -76.4% | -81.1% | -96.3% | -95.4% | — | — | — | — | — | |
| Current Ratio | 5.97 | 7.13 | 5.33 | 6.58 | 5.97 | 7.09 | 6.87 | 5.21 | 5.16 | 6.54 | 6.35 | 7.19 | 6.89 |
| — | +0.6% | -22.4% | +26.3% | +15.6% | +8.4% | +8.3% | -27.6% | -25.1% | +29.7% | -20.0% | -5.3% | +0.2% | |
| Quick Ratio | 2.90 | 3.65 | 2.78 | 3.36 | 2.90 | 3.26 | 2.80 | 1.86 | 1.69 | 2.64 | 2.49 | 2.73 | 2.73 |
| — | +11.8% | -1.0% | +80.6% | +71.8% | +23.4% | +12.6% | -31.8% | -38.1% | +92.0% | -8.9% | -14.5% | -1.3% | |
| Interest Coverage | 9.98 | 30.45 | 23.34 | 17.66 | 13.31 | 11.33 | 10.36 | 5.79 | 2.29 | 1.36 | -0.08 | -0.13 | -1.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonADMA Biologics, Inc.'s current P/E is 19.2x. The average P/E over the last 4 quarters is 27.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ADMA Biologics, Inc.'s current operating margin is 32.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ADMA Biologics, Inc.'s business trajectory between earnings reports.